ClinicalTrials.gg
Active, not recruitingNCT04538742DB-07Updated Dec 8, 2025

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

A Phase 1/2 interventional study of Trastuzumab deruxtecan and Durvalumab in Metastatic Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 72 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
15th of 58
245 · median 139
Started
2020
with 8 others
Phase 1/2
4 of 58
2 open now
Primary completion
2025-01
later than 4 of 44 live
Registered
13th of 58
by date
Lead sponsor
9 of 58
AstraZeneca

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 15th largest by enrollment, is one of 9 that started in 2020, is one of 4 in phase 1/2, reaches primary completion later than 4 of the 44 other live ones, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer

Read the detailed description

This study is modular in design allowing assessment of safety, tolerability and anti-tumour activity of T-DXd in combination with other anti-cancer agents. Combination-treatment modules will have 2 parts: a dose-finding phase (Part 1), and a dose expansion phase (Part 2); the recommended Phase 2 dose (RP2D) determined in Part 1 will be used for the dose-expansion in Part 2.

The target population of interest in this study is patients with HER2-positive (as per ASCO/CAP 2018 guidelines) advanced/MBC inclusive of patients with active and stable brain metastases. Part 1 of each module will enroll patients with locally assessed HER2-positive advanced/MBC in second-line or later patients. Part 2 of each module will enroll patients with locally assessed HER2-positive breast cancer who have not received prior treatment for advanced/metastatic disease.

03

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • Breast Cancer
  • HER2-positive
  • Brain Metastases
  • Trastuzumab Deruxtecan
  • T-DXd
  • DS-8201a
  • DESTINY-Breast07
  • Anti-HER2 Antibody Drug Conjugate (ADC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must be at least 18 years of age
  • documented breast cancer that:

    1. Is advanced/unresectable (patients that can be treated with curative intent are not eligible) or
    2. -positive (IHC 3+ or IHC 2+/ISH+) based on local assessment. The local HER2 result must be from a tumour sample obtained in the metastatic setting.
    3. Is documented as hormone receptor-positive (estrogen or progesterone receptor) or negative in the metastatic setting
  • Patient must have adequate tumor sample from the metastatic setting for biomarker assessment
  • Performance Status of 0 or 1
  • Part 1

    1. Disease progression on or after the last systemic therapy prior to starting study treatment
    2. At least 1 prior treatment line in metastatic setting required.
  • Part 2 (Modules 0 - 5)

    a) No for advanced/MBC allowed

  • Part 2 (Module 6 and 7) a) Zero or one prior lines of therapy for advanced/MBC allowed

CNS Inclusion

  • Modules 0 - 5 Patients must have no or stable brain metastases.
  • Module 6 and 7 Patients must have untreated brain metastases not needing local therapy or previously treated brain metastases that have progressed since prior local therapy

Key Exclusion Criteria:

  • Uncontrolled or significant cardiovascular disease
  • Active or prior documented (non-infectious) ILD/pneumonitis that required , or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Lung-specific intercurrent illnesses
  • Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
  • Spinal cord compression or a history of
  • Prior treatment with
  • Prior treatment with an ADC containing a topoisomerase I inhibitor
  • Prior treatment with tucatinib

CNS Exclusion

  • Modules 0 - 5: Has untreated brain metastasis
  • Module 6 and 7: Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg dexamethasone or any brain lesion thought to require immediate local therapy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Module 1- T-DXd and Durvalumab

    T-DXd and Durvalumab

    Drug: Trastuzumab deruxtecan · Drug: Durvalumab

  • Experimental
    Module 2- T-DXd and Pertuzumab

    T-DXd and Pertuzumab

    Drug: Trastuzumab deruxtecan · Drug: Pertuzumab

  • Experimental
    Module 3- T-DXd and Paclitaxel

    T-DXd and Paclitaxel (Arm not initiated in Part 2)

    Drug: Trastuzumab deruxtecan · Drug: Paclitaxel

  • Experimental
    Module 4- T-DXd and Durvalumab and Paclitaxel

    T-DXd and Durvalumab and Paclitaxel (Arm not initiated in Part 1 and Part 2)

    Drug: Trastuzumab deruxtecan · Drug: Durvalumab · Drug: Paclitaxel

  • Experimental
    Module 0- T-DXd

    T-DXd

    Drug: Trastuzumab deruxtecan

  • Experimental
    Module 5 - T-DXd and Tucatanib

    T-DXd and tucatinib (Arm not initiated in Part 2)

    Drug: Trastuzumab deruxtecan · Drug: Tucatinib

  • Experimental
    Module 6 - T-DXd and Tucatinib

    T-DXd and tucatinib in patients with active brain metastases (Part 2 Only) (Arm not initiated)

    Drug: Trastuzumab deruxtecan · Drug: Tucatinib

  • Experimental
    Module 7 - T-DXd

    T-DXd monotherapy in patients with active brain metastases (Part 2 Only)

    Drug: Trastuzumab deruxtecan

Interventions

  • T-DXd: administered as an IV infusion

    Also known as: DS-8201a, T-DXd

  • Durvalumab: administered as an IV infusion

    Also known as: MEDI4736

  • Paclitaxel: administered as an IV infusion

  • Pertuzumab: administered as an IV infusion

  • Tucatinib administered orally (tablet) twice daily

    Also known as: ONT-380

06

What researchers measure

Primary outcomes

  1. Occurrence of adverse events (AEs)- Part 1

    Occurrence of AEs in Part 1 graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 53 months

  2. Occurrence of serious adverse events (SAEs)- Part 1

    Occurrence of SAEs in Part 1 graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 53 months

  3. Occurrence of adverse events (AEs)- Part 2

    Occurrence of AEs in Part 2 graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 53 months

  4. Occurrence of serious adverse events (SAEs)- Part 2

    Occurrence of SAEs in Part 2 graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 53 months

Secondary outcomes

  1. Objective Response Rate (ORR)- Part 1 and Part 2

    ORR is defined as the proportion of patients who have a CR or PR, as determined by the Investigator at local site per RECIST 1.1.

    Time frame: Until progression, assessed up to approximately 53 months

  2. Progression Free Survival (PFS)- Part 1 and Part 2

    PFS is defined as time from the date of randomization until the date of progression as assessed by the Investigator at local site per RECIST 1.1, or death due to any cause.

    Time frame: Until progression, assessed up to approximately 53 months

  3. Progression Free Survival 2 (PFS2)- Part 2

    PFS2 is defined as time from the date of randomisation until the date of progression on next line treatment (the earliest of the progression event subsequent to first subsequent anticancer therapy) or death; second progression will be defined according to local standard clinical practice.

    Time frame: Assessed up to approximately 53 months

  4. Duration of Response (DoR)- Part 2

    DoR is defined as time from the date of first documented response until the date of documented progression or death in the absence of disease progression.

    Time frame: Until progression, assessed up to approximately 53 months

  5. Overall Survival (OS)- Part 2

    OS is defined as time from the date of randomisation until the date of death due to any cause.

    Time frame: Until death, assessed up to approximately 53 months

  6. Serum Concentration of Trastuzumab Deruxtecan (T-DXd)

    Determination of trastuzumab deruxtecan concentration in serum at different time points after trastuzumab deruxtecan administration

    Time frame: While on study drug up to study completion, approximately 53 months

  7. Serum Concentration of Durvalumab

    Determination of durvalumab concentration in serum at different time points after administration

    Time frame: While on study drug up to study completion, approximately 53 months

  8. Serum Concentration of Pertuzumab

    Determination of pertuzumab concentration in serum at different time points after administration

    Time frame: While on study drug up to study completion, approximately 53 months

  9. Plasma Concentration of Paclitaxel

    Determination of paclitaxel concentration in plasma at different time points after administration

    Time frame: While on study drug up to study completion, approximately 53 months

  10. Plasma Concentration of Tucatinib

    Determination of tucatinib concentration in plasma at different time points after administration

    Time frame: While on study drug up to study completion, approximately 53 months

  11. Immunogenicity of trastuzumab deruxtecan

    Percentage of patients who develop ADA for trastuzumab deruxtecan

    Time frame: Up to follow-up period, approximately 53 months

  12. Immunogenicity of Durvalumab

    Percentage of patients who develop ADA for durvalumab

    Time frame: Up to follow-up period, approximately 53 months

  13. Immunogenicity of Pertuzumab

    Percentage of patients who develop ADA for pertuzumab

    Time frame: Up to follow-up period, approximately 53 months

07

Study locations

72 sites
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    Harrison, New York 10604, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Columbus, Ohio 43219, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30150-274, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20560-120, Brazil
  • Research Site
    São Paulo, 01317-001, Brazil
  • Research Site
    São Paulo, 04029-000, Brazil
  • Research Site
    Sorocaba, 18030-005, Brazil
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
  • Research Site
    Québec, Quebec G1S 4L8, Canada
  • Research Site
    Toronto, M5G 2M9, Canada
  • Research Site
    Villejuif, 94805, France
  • Research Site
    München, 81675, Germany
  • Research Site
    Würzburg, 97080, Germany
  • Research Site
    Delhi, 110085, India
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Madurai, 625107, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Rome, 168, Italy
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Koszalin, 75-581, Poland
  • Research Site
    Lodz, 90-242, Poland
  • Research Site
    Lublin, 20-090, Poland
  • Research Site
    Moscow, 105229, Russia
  • Research Site
    Moscow, 109240, Russia
  • Research Site
    Moscow, 111123, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 117997, Russia
  • Research Site
    Moscow, 121205, Russia
  • Research Site
    Moscow, 143423, Russia
  • Research Site
    Saint Petersburg, 195271, Russia
  • Research Site
    Saint Petersburg, 196603, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Busan, 602-739, South Korea
  • Research Site
    Seoul, 02841, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 08003, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Hualien City, 970, Taiwan
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 10048, Taiwan
  • Research Site
    Taipei, 10449, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taipei, 114, Taiwan
  • Research Site
    Taipei, 235, Taiwan
  • Research Site
    Taoyuan City, 333, Taiwan
  • Research Site
    Ankara, 6100, Turkey (Türkiye)
  • Research Site
    Edirne, 22030, Turkey (Türkiye)
  • Research Site
    Istanbul, 34662, Turkey (Türkiye)
  • Research Site
    Istanbul, 34722, Turkey (Türkiye)
  • Research Site
    Izmir, 35100, Turkey (Türkiye)
  • Research Site
    Buckhurst Hill, IG9 5HX, United Kingdom
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jan 2025, 49 months.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 49 months is below that.

Counting every sponsor, half of 327 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2020
First posted
Sep 4, 2020
StartActual
Dec 28, 2020
Primary completionActual
Jan 31, 2025
CompletionEst.
Jan 31, 2030
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04538742
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo Company, Limited
Responsible party
Sponsor
First posted
Sep 4, 2020
Start date
Dec 28, 2020
Primary completion
Jan 31, 2025
Completion
Jan 31, 2030 (estimated)
Last update
Dec 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab deruxtecan · Tucatinib

Start the discussion